PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,754,862 | -33.0% | 3,942,138 | +11.0% | 0.00% | -20.0% |
| Q2 2023 | $98,105,853 | +76.7% | 3,551,986 | +47.2% | 0.01% | +66.7% |
| Q1 2023 | $55,514,803 | -32.9% | 2,413,701 | -68.2% | 0.00% | +50.0% |
| Q4 2022 | $82,761,646 | +109.9% | 7,585,852 | +62.2% | 0.00% | 0.0% |
| Q3 2022 | $39,424,000 | -26.4% | 4,676,682 | -31.0% | 0.00% | -33.3% |
| Q2 2022 | $53,600,000 | -30.5% | 6,776,269 | +108.1% | 0.00% | -25.0% |
| Q1 2022 | $77,121,000 | -12.3% | 3,256,808 | +26.6% | 0.00% | 0.0% |
| Q4 2021 | $87,948,000 | +146.4% | 2,571,570 | +27.7% | 0.00% | +100.0% |
| Q3 2021 | $35,688,000 | -45.3% | 2,013,979 | +38.5% | 0.00% | -33.3% |
| Q2 2021 | $65,283,000 | +47.2% | 1,454,620 | -15.1% | 0.00% | 0.0% |
| Q1 2021 | $44,358,000 | +48.2% | 1,712,683 | +15.4% | 0.00% | +50.0% |
| Q4 2020 | $29,924,000 | +32.6% | 1,484,316 | +28.6% | 0.00% | 0.0% |
| Q3 2020 | $22,572,000 | +233.8% | 1,154,553 | +201.5% | 0.00% | – |
| Q2 2020 | $6,762,000 | +201.3% | 382,894 | +20.5% | 0.00% | – |
| Q1 2020 | $2,244,000 | -5.9% | 317,792 | -6.0% | 0.00% | – |
| Q4 2019 | $2,384,000 | -37.0% | 338,170 | +7.3% | 0.00% | – |
| Q3 2019 | $3,784,000 | +19.0% | 315,043 | +19.9% | 0.00% | – |
| Q2 2019 | $3,181,000 | +1697.2% | 262,710 | +1769.6% | 0.00% | – |
| Q1 2019 | $177,000 | +84.4% | 14,052 | -1.7% | 0.00% | – |
| Q4 2018 | $96,000 | -36.4% | 14,298 | -2.3% | 0.00% | – |
| Q3 2018 | $151,000 | +57.3% | 14,640 | +1.8% | 0.00% | – |
| Q2 2018 | $96,000 | -92.7% | 14,378 | -90.6% | 0.00% | – |
| Q1 2018 | $1,313,000 | -53.9% | 152,982 | +11.8% | 0.00% | – |
| Q4 2017 | $2,847,000 | +37.5% | 136,844 | +16.8% | 0.00% | – |
| Q3 2017 | $2,071,000 | +63.1% | 117,183 | +4.2% | 0.00% | – |
| Q2 2017 | $1,270,000 | +6.5% | 112,474 | +20.9% | 0.00% | – |
| Q1 2017 | $1,192,000 | -41.2% | 93,063 | +1.0% | 0.00% | – |
| Q4 2016 | $2,028,000 | +57.0% | 92,163 | +50.8% | 0.00% | – |
| Q3 2016 | $1,292,000 | – | 61,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |